Dr. Khanna has received consulting fees, speaking fees, and/or honoraria from United Therapeutics, Roche, Bristol-Myers Squibb, Gilead, Pfizer, Digna Biotech, and Impact Pharmaceutical Services (less than $10,000 each) and from Actelion (more than $10,000).
Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension
Article first published online: 27 NOV 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 65, Issue 12, pages 3194–3201, December 2013
How to Cite
Khanna, D., Gladue, H., Channick, R., Chung, L., Distler, O., Furst, D. E., Hachulla, E., Humbert, M., Langleben, D., Mathai, S. C., Saggar, R., Visovatti, S., Altorok, N., Townsend, W., FitzGerald, J. and McLaughlin, V. V. (2013), Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension. Arthritis & Rheumatism, 65: 3194–3201. doi: 10.1002/art.38172
- Issue published online: 27 NOV 2013
- Article first published online: 27 NOV 2013
- Accepted manuscript online: 10 SEP 2013 03:34PM EST
- Manuscript Accepted: 22 AUG 2013
- Manuscript Received: 1 APR 2013
- Scleroderma Foundation
- Pulmonary Hypertension Association
- Educational grants from Actelion
- United Therapeutics
- NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases). Grant Number: K24-AR-063120-02
- Scleroderma Research Foundation
- National Heart, Lung, and Blood Institute. Grant Number: K23-HL-093387
- 7ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.J Am Coll Cardiol2009;53:1573–619., , , , , , et al.
- 10The RAND/UCLA appropriateness method user's manual.Santa Monica (CA):RAND Corporation;2001., , , , , , et al.
- 122012 American College of Rheumatology guidelines for management of gout. Part 1. Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.Arthritis Care Res (Hoboken)2012;64:1431–46., , , , , , et al.
- 13American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis [published erratum appears in Arthritis Care Res (Hoboken) 2012;64:464].Arthritis Care Res (Hoboken)2010;62:1515–26., , , , , , et al.
- 15Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review.Semin Arthritis Rheum2013. E-pub 9/10/13., , , , .
- 17QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.Ann Intern Med2011;155:529–36., , , , , , et al.
- 20National Conference on chronic disease.Public Health Nurs1951;43:344.
- 22Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp G, editors.Mixed connective tissue disease and anti-nuclear antibodies.Amsterdam:Elsevier;1987. p.33–40., .
- 24Syndrom de Sharp. In: Kahn MF, Peltier AP, Meyer O, Piette JC, editors.Les maladies systemiques. 3rd ed.Paris:Flammarion;1991. p.545–556., .
- 25Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors.Mixed connective tissue disease and anti-nuclear antibodies.Amsterdam:Elsevier;1987. p.41–8., , .
- 26ItinerAIR-Sclerodermie Study Group.The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.Arthritis Rheum2009;60:1831–9., , , , , , et al, and the
- 30DETECT Study Group.Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.Ann Rheum Dis2013. E-pub ahead of print., , , , , , et al, on behalf of the
- 33Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Investigators.Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis—results from the PHAROS registry.Ann Rheum Dis2012;71:1335–42., , , , , , et al, for the
- 36Early detection and management of pulmonary arterial hypertension.Eur Respir Rev2012;21:306–12., , .
- 37The Criteria Committee of the New York Heart Association.Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed.Boston:Little Brown;1994. p.253–6.
- 40High N-terminal pro–brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.Arthritis Rheum2008;58:284–91., , , , , , et al.
- 46Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension in patients with systemic sclerosis.Eur Heart J2010;31:869–70., , , , , , et al.
- 49Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.J Am Soc Echocardiogr2010;23:685–713., , , , , , et al.
- 512012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care Res (Hoboken)2012;64:625–39., , , , , , et al.